Statistical controversies in clinical research: data access and sharing-can we be more transparent about clinical research? Let's do what's right for patients.
Repository Usage Stats
Calls for greater transparency and 'open data access' in clinical research are widespread, from sources including the Executive Office of the President, which in 2013 called for increased access to the results of federally funded research. In 2015, The Institute of Medicine issued a report advocating for a multi-stakeholder effort to foster responsible data sharing, and there are many others. Open science is good for researchers, good for innovation, and good for patients. The question at the center of the open-science efforts for clinical trials should not be whether data should be shared, but rather how we can usher in responsible methods for doing so. Unfortunately, there remain numerous perceived barriers to complete transparency around clinical trial data. This paper reviews the current status of data disclosure, the barriers to achieving it and a suggestion for the future.
Published Version (Please cite this version)10.1093/annonc/mdx123
Publication InfoRockhold, Frank Wesley (2017). Statistical controversies in clinical research: data access and sharing-can we be more transparent about clinical research? Let's do what's right for patients. Ann Oncol, 28(8). pp. 1734-1737. 10.1093/annonc/mdx123. Retrieved from http://hdl.handle.net/10161/15407.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor of Biostatistics & Bioinformatics
Frank has had diverse research interests and consulting experience in industry and academia including clinical trials design, data monitoring, benefit/risk, and most recently, safety and pharmacovigilance. He has been a leader in the scientific community in promoting data disclosure and transparency in clinical research. In addition his role of full-time Professor of Biostatistics and Bioinformatics at Duke Clinical Research Institute, Frank is also Managing Partner of HunterRock